Abstract
Hepatic encephalopathy (HE) is a major complication of liver disease that leads to significant morbidity and mortality. Caring for hospitalized patients with HE is becoming more complex, and the economic burden of HE continues to rise. Defining and diagnosing HE, particularly covert HE (CHE), remain challenging. In this article, we review new tools and those currently under development for the diagnosis of CHE and the latest advances in the acute and long-term management of overt HE (OHE) and CHE. In particular, we review the latest data on the use of lactulose and rifaximin for treatment of OHE and summarize the data on adjunctive agents such as sodium benzoate and probiotics.
Original language | English (US) |
---|---|
Pages (from-to) | 91-100 |
Number of pages | 10 |
Journal | Gastroenterology and Hepatology |
Volume | 12 |
Issue number | 2 |
State | Published - Feb 1 2016 |
Keywords
- Covert hepatic encephalopathy
- Hepatic encephalopathy
- Lactulose
- Overt hepatic encephalopathy
- Rifaximin
ASJC Scopus subject areas
- Hepatology
- Gastroenterology